Lexicon to Present Positive Top-Line Phase 2 Results for LX1031 in Non-Constipating Irritable Bowel Syndrome at GASTRO 2009
- LX1031 represents a first-in-class compound for IBS - Inhibitor of tryptophan hydroxylase, a key enzyme in serotonin production - First demonstration of new mechanism of action in treatment of IBS Presentation summary will be available at www.lexpharma.com on November 25, 2009
THE WOODLANDS, Texas, Nov. 23 /PRNewswire-FirstCall/ -- Lexicon
Pharmaceuticals, Inc. (NASDAQ:LXRX) , announced today that top-line
data from its Phase 2 clinical study with LX1031 in patients with
non-constipating irritable bowel syndrome (IBS) will be presented
at GASTRO 2009 in London this week. Results from the study, which
showed a significant improvement in IBS symptoms, will be presented
by Dr. Philip M. Brown, Lexicon's senior vice president of clinical
development, on November 25, 2009 at 2:30 pm local time at the
session entitled, "Therapeutic insights in functional digestive
disorders."
The GASTRO 2009 meeting is a joint world conference in the area
of gastroenterology. This meeting will bring together the world's
leading organizations - the United European Gastroenterology
Federation (UEGF), World Gastroenterology Organization (WGO), World
Organization of Digestive Endoscopy (OMED) and the British Society
of Gastroenterology (BSG) - for one of the biggest congresses in
this area of medicine with more than 12,000 scientists from around
the world expected to attend.
A summary of the GASTRO 2009 presentation (with audio) will be
available on Lexicon's corporate website at www.lexpharma.com on
November 25, 2009.
About LX1031
LX1031 is an orally available, locally acting inhibitor of
tryptophan hydroxylase (TPH), an enzyme necessary for the
biosynthesis of serotonin. LX1031 acts by selectively decreasing
the production of serotonin in the gastrointestinal tract.
Discovered and developed by Lexicon, LX1031 is the first TPH
inhibitor ever to be evaluated in human clinical trials for the
treatment of IBS. In Phase 1 clinical trials, all dose levels of
the drug were well tolerated, and no dose-limiting toxicities were
observed. LX1031 was also shown to reduce levels of urinary 5-HIAA,
a biomarker of serotonin production.
LX1031 is being developed in collaboration with Symphony Capital LLC. About Irritable Bowel Syndrome
Irritable bowel syndrome is a disorder most commonly
characterized by cramping, abdominal pain, bloating, constipation
or diarrhea. According to the International Foundation for
Functional Gastrointestinal Disorders, IBS affects between 25 and
45 million people in the United States. Symptoms of IBS are
believed to be mediated through serotonin, which has been shown to
play an important role in modulating motility and signaling
feelings of GI discomfort.
About Lexicon
Lexicon is a biopharmaceutical company focused on discovering
and developing breakthrough treatments for human disease. Lexicon
currently has five drug candidates in development for autoimmune
disease, carcinoid syndrome, diabetes, glaucoma and irritable bowel
syndrome, all of which were discovered by the company's research
team. The company has used its proprietary gene knockout technology
to identify more than 100 promising drug targets. Lexicon has
focused drug discovery efforts on these biologically-validated
targets to create its extensive pipeline of clinical and
preclinical programs. For additional information about Lexicon and
its programs, please visit www.lexpharma.com.
Safe Harbor Statement
This press release contains "forward-looking statements,"
including statements relating to Lexicon's plans for further
clinical development of LX1031 and the potential therapeutic and
commercial potential of LX1031. This press release also contains
forward-looking statements relating to Lexicon's growth and future
operating results, discovery and development of products other than
LX1031, strategic alliances and intellectual property, as well as
other matters that are not historical facts or information. All
forward-looking statements are based on management's current
assumptions and expectations and involve risks, uncertainties and
other important factors, specifically including those relating to
the clinical development of LX1031 and preclinical and clinical
development of Lexicon's other potential drug candidates and
Lexicon's ability to successfully advance additional candidates
into preclinical and clinical development, obtain necessary
regulatory approvals, achieve its operational objectives, obtain
patent protection for its discoveries and establish strategic
alliances, as well as additional factors relating to manufacturing,
intellectual property rights, and the therapeutic or commercial
value of its drug candidates, that may cause Lexicon's actual
results to be materially different from any future results
expressed or implied by such forward-looking statements.
Information identifying such important factors is contained under
"Factors Affecting Forward-Looking Statements" and "Risk Factors"
in Lexicon's annual report on Form 10-K for the year ended December
31, 2008, as filed with the Securities and Exchange Commission.
Lexicon undertakes no obligation to update or revise any such
forward-looking statements, whether as a result of new information,
future events or otherwise.
Source: Lexicon Pharmaceuticals, Inc.
CONTACT: Jason Ray, Manager, Corporate Communications and
Investor
Relations of Lexicon, +1-281-863-3225, jray@lexpharma.com
Web Site: http://www.lexpharma.com/
Posted: November 2009
